
Biomarker Analysis in Clinical Trials with R
Nusrat Rabbee(Author)
CRC Press
1st Edition
Published on 1. April 2020
Book
Hardback
204 pages
978-1-138-36883-5 (ISBN)
Description
The world is awash in data. This volume of data will continue to increase. In the pharmaceutical industry, much of this data explosion has happened around biomarker data. Great statisticians are needed to derive understanding from these data. This book will guide you as you begin the journey into communicating, understanding and synthesizing biomarker data. -From the Foreword, Jared Christensen, Vice President, Biostatistics Early Clinical Development, Pfizer, Inc.
Biomarker Analysis in Clinical Trials with R offers practical guidance to statisticians in the pharmaceutical industry on how to incorporate biomarker data analysis in clinical trial studies. The book discusses the appropriate statistical methods for evaluating pharmacodynamic, predictive and surrogate biomarkers for delivering increased value in the drug development process. The topic of combining multiple biomarkers to predict drug response using machine learning is covered. Featuring copious reproducible code and examples in R, the book helps students, researchers and biostatisticians get started in tackling the hard problems of designing and analyzing trials with biomarkers.
Features:
Analysis of pharmacodynamic biomarkers for lending evidence target modulation.
Design and analysis of trials with a predictive biomarker.
Framework for analyzing surrogate biomarkers.
Methods for combining multiple biomarkers to predict treatment response.
Offers a biomarker statistical analysis plan.
R code, data and models are given for each part: including regression models for survival and longitudinal data, as well as statistical learning models, such as graphical models and penalized regression models.
Biomarker Analysis in Clinical Trials with R offers practical guidance to statisticians in the pharmaceutical industry on how to incorporate biomarker data analysis in clinical trial studies. The book discusses the appropriate statistical methods for evaluating pharmacodynamic, predictive and surrogate biomarkers for delivering increased value in the drug development process. The topic of combining multiple biomarkers to predict drug response using machine learning is covered. Featuring copious reproducible code and examples in R, the book helps students, researchers and biostatisticians get started in tackling the hard problems of designing and analyzing trials with biomarkers.
Features:
Analysis of pharmacodynamic biomarkers for lending evidence target modulation.
Design and analysis of trials with a predictive biomarker.
Framework for analyzing surrogate biomarkers.
Methods for combining multiple biomarkers to predict treatment response.
Offers a biomarker statistical analysis plan.
R code, data and models are given for each part: including regression models for survival and longitudinal data, as well as statistical learning models, such as graphical models and penalized regression models.
Reviews / Votes
I can imagine applied statisticians having a hardcover version on their desks near their computer, in a somewhat overused condition, referring to this every now and then for the implementation of the described methods in practice. Goal achieved in such a case.- Christos T. Nakas, International Society for Clinical Biostatistics, 71, 2021
More details
Series
Language
English
Place of publication
London
United Kingdom
Publishing group
Taylor & Francis Ltd
Target group
College/higher education
Illustrations
38 s/w Abbildungen, 18 s/w Tabellen
18 Tables, black and white; 38 Illustrations, black and white
Dimensions
Height: 240 mm
Width: 161 mm
Thickness: 17 mm
Weight
514 gr
ISBN-13
978-1-138-36883-5 (9781138368835)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions

Nusrat Rabbee
Biomarker Analysis in Clinical Trials with R
Book
12/2021
1st Edition
Chapman & Hall/CRC
€69.30
Shipment within 10-20 days

Nusrat Rabbee
Biomarker Analysis in Clinical Trials with R
E-Book
03/2020
1st Edition
Chapman & Hall/CRC
€63.49
Available for download

Nusrat Rabbee
Biomarker Analysis in Clinical Trials with R
E-Book
03/2020
1st Edition
Chapman & Hall/CRC
€63.49
Available for download
Person
Nusrat Rabbee is a biostatistician and data scientist at Rabbee & Associates, where she creates innovative solutions to help companies accelerate drug and diagnostic development for patients. Her research interest lies in the intersection of data science and personalized medicine. She has extensive experience in bioinformatics, clinical statistics and high-dimensional data analyses. She has co-discovered the RLMM algorithm for genotyping Affymetrix SNP chips and co-invented a high-dimensional molecular signature for cancer. She has spent over 17 years in the pharmaceutical and diagnostics industry focusing on biomarker development. She has taught statistics at UC Berkeley for 4 years.
Content
Section I Pharmacodynamic Biomarkers 1. Introduction 2. Toxicology Studies 3. Bioequivalence Studies 4. Cross-Sectional Profile of Pharmacodynamics Biomarkers 5. Timecourse Profile of Pharmacodynamics Biomarkers 6. Evaluating Multiple Biomarkers Section II Predictive Biomarkers 7. Introduction 8. Operational Characteristics of Proof-of-Concept Trials with Biomarker-Positive and -Negative Subgroups 9. A Framework for Testing Biomarker Subgroups in Confirmatory Trials 10. Cutoff Determination of Continuous Predictive Biomarker for a Biomarker-Treatment Interaction 11. Cutoff Determination of Continuous Predictive Biomarker Using Group Sequential Methodology 12. Adaptive Threshold Design 13. Adaptive Seamless Design (ASD) Section III Surrogate Endpoints 14. Introduction 15. Requirement # 1: Trial Level - Correlation Between Hazard Ratios in Progression-Free Survival and Overall Survival Across Trials 16. Requirement # 2: Individual Level - Assess the Correlation Between the Surrogate and True Endpoints After Adjusting for Treatment (R2 indiv) 17. Examining the Proportion of Treatment Effect in AIDS Clinical Trials 18. Concluding Remarks Section IV Combining Multiple Biomarkers 19. Introduction 20. Regression-Based Models 21. Tree-Based Models 22. Cluster Analysis 23. Graphical Models Section V Biomarker Statistical Analysis Plan